High hopes for prasugrel hit by safety worries
Clinical trials of a much-anticipated compound from Eli Lilly brought mixed results, causing analysts to further cool on the drug.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.